

Author Acknowledgments

RAPS and the lead editors, Anu Gaur and Karen Zhou, thank the following subject matter experts for sharing their experience and knowledge and volunteering their time to contribute to this first edition of Postmarket Requirements for Medical Devices: A Practical Guide.

Rajaram Balasubramanian,
RAC-US, RAC-EU, PMP

Director, Regulatory Affairs
and Quality Assurance,
TIMEA
Elekta Medical Systems India
Pvt Ltd
India
Chapters 9 and 10

Karen Fan, MSc, RAC, Peng,
PMP

EU MDR Consultant
Johnson & Johnson Surgical
Vision Inc.
Canada
Chapter 3

Anu Gaur, PhD, MBA,
MSRA, RAC-US,
RAC-Global

President
SYNERGY Global
Regulatory Affairs
Consultancy, Inc.
US
*Lead Editor, Preface, and
Chapter 1*

Michelle Jump, MSc, RAC

CEO
MedSec
US
Chapter 18

Barbara Leukers, Dipl.
Chem (FH), RAC

Consultant
Leukers-Consulting
Germany
Chapter 8

Shikha Malik, MPharm, MS,
RAC-Devices

Senior Regulatory Affairs
Specialist
Medtronic
US
Chapter 2

Cathy Matthews, MSc

Regulatory Affairs Specialist
Edwards Lifesciences Canada
Inc.
Canada
Chapter 4

Sharon Perez, PhD

Vice President, Global
Medical Safety
Novocure
US
Chapters 11 through 17

Sharad Mi Shukla, RAC-US,
RAC EU

Director Regulatory Affairs
MedTech
Johnson & Johnson
Singapore
Chapters 9 and 10

Julia Stindl, PhD

Head of Global Post-Market
Safety
Novocure
Germany
Chapters 11, 12, 13, 16, and 17

Ana Subramanian, MSc,
PhD, RAC

Canada
Chapters 6 and 8

Echo Yu, MSc, RAC-Global

QA/RA Director
Sinocare Meditech, Inc.
Canada
Chapter 7

Karen Zhou, JD, MS, RAC-
Devices, RAC-Global

Faculty, MS Regulatory
Affairs Program
Northeastern University
Canada
*Lead Editor, Preface, and
Chapter 5*

SECTION

I

North America:
United States
and Canada

Section I: North America: United States and Canada

Chapter 1: Postmarket Compliance and Product Changes: US

1

Postmarket Compliance and Product Changes: US

By Anu Gaur, PhD, MBA, MSRA, RAC-US, RAC-Global

Introduction

In the US, the legislative requirements set forth in Section 522 of the Food, Drug, and Cosmetics Act (FD&C Act) mandate postmarket surveillance for medium (Class II) and high-risk (Class III) medical devices. The US Food and Drug Administration's (FDA) Center for Devices and Radiological Health (CDRH) is responsible for protecting and promoting the public health by ensuring timely and continued access to safe, effective, and high-quality medical devices and safe radiation-emitting products for healthcare.¹

In general, postmarket surveillance refers to the monitoring process for legally marketed medical products, which constitutes an active, systematic, and scientifically valid collection of data related to their intended clinical use, data analysis, and its interpretation for safety and performance outcomes. In this process, the monitoring of postmarket product-related adverse events (AEs), including their frequency, occurrence, and severity, applies to any product-related safety concerns, public health impact, and justification for a medical device's safety, performance, and efficacy.

FDA requirements for medical device reporting were enacted in December 1984. However, the US Congress first granted FDA

the authority to enforce and require certain medical device manufacturers to conduct postmarket surveillance, per Section 522 of the Safe Medical Devices Act (SMDA) of 1990. The SMDA further provided FDA with two additional post-market activities, including:

1. Postmarket surveillance for the monitoring of products after their market clearance
2. Device tracking for maintaining traceability of certain devices to the user level

Section 212 of the Food and Drug Modernization Act (FDAMA) of 1997 further amended the Section 522 in part to stipulate that the postmarket surveillance may be required by order for any Class II or Class III device the failure of which would be reasonably likely to have serious adverse health consequences, which is intended to be implanted in the human body for more than one year, or which is a life-sustaining or life-supporting device used outside a device user facility.²⁻⁴

Under Section 212 of FDAMA, FDA is authorized to require a prospective surveillance period of up to 36 months, unless FDA determines a longer period is necessary, and there is a mutual agreement between FDA and the